GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation Therapy (SBRT) in patients with pancreatic cancer.
Pancreatic Cancer
DRUG: Cyclophosphamide|DRUG: Nivolumab|DRUG: GVAX Pancreas Vaccine|RADIATION: Stereotactic Body Radiation (SBRT)
CD8+ T Cell Density in Tumor Tissue, Mean CD8+ T cell density \[log(cells per mm\^2)\], found in resected surgical tissue by Immunohistochemistry (IHC)., evaluated at time of surgery, approximately 2 months from first dose of study drug
Pathologic Complete Response (pCR) Rate at Surgical Resection, Number of patients with a pathologic complete response (pCR) rate at surgical resection. A pCR is defined as no viable residual tumor remaining at the time of evaluation., Assessed at time of surgical resection, approximately 2 months after first dose of study drug
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation Therapy (SBRT) in patients with pancreatic cancer.